Endocrine Testing Market

Endocrine Testing Market - Global Industry Analysis, Size, Share, Growth Trends and Forecast, 2019 - 2027

  • According to Transparency Market Research’s latest report on the global endocrine testing market for the historical period 2017–2018 and forecast period 2019–2027, rise in prevalence of endocrine and metabolic disorders to escalate the growth of global endocrine testing market. Moreover, rising cases of diabetes are expected to fuel growth of the endocrine testing market
  • According to the report, the global endocrine testing market was valued at US$ 5.5 Bn in 2018 and is anticipated to expand at a CAGR of 6.4% from 2019 to 2027
fa global endocrine testing market

Rise in Focus on Research & Development and Surge in Number of People with Diabetes Mellitus: Key Drivers of Global Endocrine Testing Market

  • Endocrine system is made up of endocrine glands that secrete hormones directly into the blood stream. Tests are performed to monitor levels of endocrine hormones (such as follicle stimulating hormone (FSH), Luteinizing Hormone (LH), estradiol, insulin and others) from biological samples. These tests aid in detection of deviation in the hormone production i.e. they help detect either hypersecretion (excess secretion) or hyposecretion (less secretion) that results in certain endocrine disorders such as infertility, menopause, thyroid dysfunction and others. Several disorders including different types of diabetes and PCOS have led to the rise in endocrine testing. For instance, according to an article published in Current Diabetes Reports, states that the prevalence of diabetes and PCOS has risen significantly. Thus, surge in number of people with endocrine and metabolic disorders is a key factor anticipated to drive the growth of endocrine testing market
  • Sedentary lifestyle and unhealthy diet are leading to surge in prevalence & incidence of diabetes. For instance, according to an article published in Diabetes Research and Clinical Practice, globally the prevalence of diabetes was 463 million in 2019 and is rising to 578 million by 2030. This is augmenting the demand for new testing methods with rapid results. To address these demands, the key players are investing in the research and development activities to develop and introduce products with new technologies, thereby boosting the growth of market.

Rise in Geriatric Population Worldwide to Propel Global Endocrine Testing Market Growth

  • Constant rise in geriatric population across the globe directly impacts the growth of endocrine testing solutions and methodologies as this population is highly susceptible to several health disorders and creates a need for effective management of the diseases globally. Old age is one of the potential risks of developing hernia, thyroid disorders and other hormone imbalances.
  • Changes in endocrine system along with age include menopause in women, loss of skeletal mass, androgen deficiency in men, increased incidence of type 2 diabetes and decrease in growth hormone. Hence, endocrine glands and organs undergo a series of changes that ultimately affects the hormone levels in an aging individual, thus, rise in the global geriatric population is one of the major factors driving the endocrine testing market

High Cost of Technology to Hamper Global Endocrine Testing Market

  • High costs involved in research and development activities for understanding several cellular mechanisms stimulated by hormones and subsequent commercialization of the tests pose a challenging task for the endocrine testing manufacturers. This in turn results in high cost of monitoring and diagnosis of hormone secretion levels in the body. For instance, Roche developed lab automation systems in the year 2013 and invested around USD 11.6 billion for research and development activities in the financial year 2019. Also, Abbott Laboratories invested around 6% - 7% of their total revenue in research and development of the novel technologies and products. This results in high cost of the end product thereby leading to high cost of diagnostic technologies that negatively impacts the market growth.
  • Enhanced access to sophisticated technological platforms is the rationale behind successful development and introduction of effective endocrine testing solutions and methodologies. Hence, limited access to advanced diagnostic procedures deprive patients from availing quality diagnosis measures and decrease the patient outcomes. Thus, high cost of testing technology might hamper the growth of the endocrine testing market.

Global Endocrine Testing Market: Competitive Landscape

  • This report profiles major players in the global endocrine testing market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global endocrine testing market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global endocrine testing market are
    • Agilent Technologies,
    • F-Hoffmann La Roche Ltd
    • AB SCIEX,
    • Thermo Fisher Scientific
    • Abbott Laboratories
    • Bio-Rad Laboratories
    • DiaSorin S.p.A
    • Beckman Coulter Inc
    • Siemens Healthineers and bioMerieux

Global Endocrine Testing Market: Key Developments

Key players in the global endocrine testing market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global endocrine testing market. A few expansion strategies adopted by players operating in the global endocrine testing market are:

  • In May 2020, Roche acquired Stratos Genomics to further develop DNA based sequencing for diagnostic use
  • In March 2020, Thermo Fisher Scientific proposed to acquire QIAGEN N.V. as this acquisition would expand its specialty diagnostics portfolio with attractive molecular diagnostics capabilities, including infectious disease testing
  • In July 2019, Thermo Fisher Scientific announced a 3 year, US$4.5 million collaboration with Ontario Institute for Cancer Research (OICR) and Genome Canada and the to develop targeted next-generation sequencing-based assays and analysis software.

The report on the global endocrine testing market discussed individual strategies, followed by company profiles of manufacturers of endocrine testing products. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global endocrine testing market.

Global Endocrine Testing Market - Segmentation

Test Type

Estradiol (E2) Test

Follicle Stimulating Hormone (FSH) Test

Human Chorionic Gonadotropin (hCG) Test

Luteinizing Hormone (LH) Test

Dehydroepiandrosterone sulfate (DHEAS) Test

Progesterone Test

Testosterone Test

Thyroid Stimulating Hormone (TSH) Test

Prolactin Test

Cortisol Test

Insulin Test

Others (Gastrin, Thymosin, Secretin, etc.)

Diagnostic Technologies

Tandem Mass Spectrometry

Immunoassay technologies

Monoclonal and Polyclonal Antibody Technologies

Sensor Technologies

Clinical Chemistry Technologies

End-user

Commercial Laboratories

Ambulatory Care Centers

Home Based tests

Physician Offices

Region

North America

Europe

Asia-Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

What is the total market worth of endocrine testing market?

Endocrine testing market to reach US$ 10.6 Bn by 2027

What is the anticipated CAGR of the endocrine testing market in the forecast period?

Endocrine testing market is anticipated to expand at a CAGR of 6.4% from 2019 to 2027

What are the key driving factors for the growth of the endocrine testing market?

Endocrine testing market is driven by rise in prevalence of endocrine and metabolic disorders

Which region is expected to project the highest market share in the global endocrine testing market?

North America accounted for a major share of the global endocrine testing market, and the trend is anticipated to continue during the forecast period

Who are the key players in the endocrine testing market?

Key players in the global endocrine testing market include Agilent Technologies, F-Hoffmann La Roche Ltd, AB SCIEX, Thermo Fisher Scientific, Abbott Laboratories

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Endocrine testing Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Market Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Endocrine testing Market Analysis and Forecasts, 2017–2027

    5. Key Insights

        5.1. Increasing prevalence and incidences of obesity and diabetes across globe

        5.2. Technological Advancements

        5.3. Key Developments 

    6. Global Endocrine testing Market Analysis and Forecasts, by Test Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Global Endocrine testing Market Value Forecast By Test Type, 2017–2027

            6.3.1. Estradiol (E2) Test

            6.3.2. Follicle Stimulating Hormone (FSH) Test

            6.3.3. Human Chorionic Gonadotropin (hCG) Test 

            6.3.4. Luteinizing Hormone (LH) Test

            6.3.5. Dehydroepiandrosterone sulfate (DHEAS) Test

            6.3.6. Progesterone Test

            6.3.7. Testosterone Test 

            6.3.8. Thyroid Stimulating Hormone (TSH) Test

            6.3.9. Prolactin Test

            6.3.10. Cortisol Test

            6.3.11. Insulin Test

            6.3.12. Others (Gastrin, Thymosin, Secretin, etc.)

        6.4. Global Endocrine testing Market Attractiveness by Test Type

    7. Global Endocrine testing Market Analysis and Forecasts, by Diagnostic Technologies

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Global Endocrine testing Market Value Forecast By Diagnostic Technologies, 2017–2027

            7.3.1. Tandem Mass Spectrometry

            7.3.2. Immunoassay technologies

            7.3.3. Monoclonal and Polyclonal Antibody Technologies

            7.3.4. Sensor Technologies

            7.3.5. Clinical Chemistry Technologies

            7.3.6. Others 

        7.4. Global Endocrine testing Market Attractiveness by Diagnostic Technologies

    8. Global Endocrine testing Market Analysis and Forecasts, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Global Endocrine testing Market Value Forecast By End-user, 2017–2027

            8.3.1. Hospitals 

            8.3.2. Commercial Laboratories 

            8.3.3. Ambulatory Care Centers

            8.3.4. Home Based tests

            8.3.5. Physician Offices

        8.4. Global Endocrine testing Market Attractiveness by End-user

    9. Global Endocrine testing Market Analysis and Forecasts, by Region

        9.1. Key Findings

        9.2. Global Endocrine testing Market Value Forecast by Region

            9.2.1. North America 

            9.2.2. Europe 

            9.2.3. Asia Pacific 

            9.2.4. Latin America 

            9.2.5. Middle East & Africa 

        9.3. Global Endocrine testing Market Attractiveness by Region

    10. North America Endocrine testing Market Analysis and Forecast

        10.1.  Introduction

            10.1.1. Key Findings

        10.2. North America Endocrine testing Market Value Forecast by Test Type, 2017–2027

            10.2.1. Estradiol (E2) Test

            10.2.2. Follicle Stimulating Hormone (FSH) Test

            10.2.3. Human Chorionic Gonadotropin (hCG) Test 

            10.2.4. Luteinizing Hormone (LH) Test

            10.2.5. Dehydroepiandrosterone sulfate (DHEAS) Test

            10.2.6. Progesterone Test

            10.2.7. Testosterone Test 

            10.2.8. Thyroid Stimulating Hormone (TSH) Test

            10.2.9. Prolactin Test

            10.2.10. Cortisol Test

            10.2.11. Insulin Test

            10.2.12. Others (Gastrin, Thymosin, Secretin, etc.)

        10.3.  North America Endocrine testing Market Value Forecast by Diagnostic Technologies, 2017–2027

            10.3.1. Tandem Mass Spectrometry

            10.3.2. Immunoassay technologies

            10.3.3. Monoclonal and Polyclonal Antibody Technologies

            10.3.4. Sensor Technologies

            10.3.5. Clinical Chemistry Technologies

            10.3.6. Others 

        10.4. North America Endocrine testing Market Value Forecast by End-user, 2017–2027

            10.4.1. Hospitals 

            10.4.2. Commercial Laboratories 

            10.4.3. Ambulatory Care Centers

            10.4.4. Home Based tests

            10.4.5. Physician Offices

        10.5.  North America Endocrine testing Market Value Forecast by Country, 2017–2027

            10.5.1. U.S.

            10.5.2. Canada

        10.6. North America Endocrine testing Market Attractiveness Analysis 

            10.6.1. By Test Type

            10.6.2. By Diagnostic Technologies

            10.6.3. By End-user

            10.6.4. By Country/Sub-region

    11. Europe Endocrine testing Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Europe Endocrine testing Market Value Forecast by Test Type, 2017–2027

            11.2.1. Estradiol (E2) Test

            11.2.2. Follicle Stimulating Hormone (FSH) Test

            11.2.3. Human Chorionic Gonadotropin (hCG) Test 

            11.2.4. Luteinizing Hormone (LH) Test

            11.2.5. Dehydroepiandrosterone sulfate (DHEAS) Test

            11.2.6. Progesterone Test

            11.2.7. Testosterone Test 

            11.2.8. Thyroid Stimulating Hormone (TSH) Test

            11.2.9. Prolactin Test

            11.2.10. Cortisol Test

            11.2.11. Insulin Test

            11.2.12. Others (Gastrin, Thymosin, Secretin, etc.)

        11.3.  Europe Endocrine testing Market Value Forecast by Diagnostic Technologies, 2017–2027

            11.3.1. Tandem Mass Spectrometry

            11.3.2. Immunoassay technologies

            11.3.3. Monoclonal and Polyclonal Antibody Technologies

            11.3.4. Sensor Technologies

            11.3.5. Clinical Chemistry Technologies

            11.3.6. Others 

        11.4. Europe Endocrine testing Market Value Forecast by End-user, 2017–2027

            11.4.1. Hospitals 

            11.4.2. Commercial Laboratories 

            11.4.3. Ambulatory Care Centers

            11.4.4. Home Based tests

            11.4.5. Physician Offices

        11.5.  Europe Endocrine testing Market Value Forecast by Country/Sub-region, 2017–2027

            11.5.1. Germany

            11.5.2. France

            11.5.3. U.K.

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6. Europe Endocrine testing Market Attractiveness Analysis 

            11.6.1. By Test Type

            11.6.2. By Diagnostic Technologies

            11.6.3. By End-user

            11.6.4. By Country/Sub-region

    12. Asia Pacific Endocrine testing Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Asia -Pacific Endocrine testing Market Value Forecast by Test Type, 2017–2027

            12.2.1. Estradiol (E2) Test

            12.2.2. Follicle Stimulating Hormone (FSH) Test

            12.2.3. Human Chorionic Gonadotropin (hCG) Test 

            12.2.4. Luteinizing Hormone (LH) Test

            12.2.5. Dehydroepiandrosterone sulfate (DHEAS) Test

            12.2.6. Progesterone Test

            12.2.7. Testosterone Test 

            12.2.8. Thyroid Stimulating Hormone (TSH) Test

            12.2.9. Prolactin Test

            12.2.10. Cortisol Test

            12.2.11. Insulin Test

            12.2.12. Others (Gastrin, Thymosin, Secretin, etc.)

        12.3.  Asia -Pacific Endocrine testing Market Value Forecast by Diagnostic Technologies, 2017–2027

            12.3.1. Tandem Mass Spectrometry

            12.3.2. Immunoassay technologies

            12.3.3. Monoclonal and Polyclonal Antibody Technologies

            12.3.4. Sensor Technologies

            12.3.5. Clinical Chemistry Technologies

            12.3.6. Others 

        12.4. Asia -Pacific Endocrine testing Market Value Forecast by End-user, 2017–2027

            12.4.1. Hospitals 

            12.4.2. Commercial Laboratories 

            12.4.3. Ambulatory Care Centers

            12.4.4. Home Based tests

            12.4.5. Physician Offices

        12.5.  Asia -Pacific Endocrine testing Market Value Forecast by Country/Sub-region, 2017–2027

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Asia -Pacific Endocrine testing Market Attractiveness Analysis 

            12.6.1. By Test Type

            12.6.2. By Diagnostic Technologies

            12.6.3. By End-user

            12.6.4. By Country/Sub-region

    13. Latin America Endocrine testing Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Latin America Endocrine testing Market Value Forecast by Test Type, 2017–2027

            13.2.1. Estradiol (E2) Test

            13.2.2. Follicle Stimulating Hormone (FSH) Test

            13.2.3. Human Chorionic Gonadotropin (hCG) Test 

            13.2.4. Luteinizing Hormone (LH) Test

            13.2.5. Dehydroepiandrosterone sulfate (DHEAS) Test

            13.2.6. Progesterone Test

            13.2.7. Testosterone Test 

            13.2.8. Thyroid Stimulating Hormone (TSH) Test

            13.2.9. Prolactin Test

            13.2.10. Cortisol Test

            13.2.11. Insulin Test

            13.2.12. Others (Gastrin, Thymosin, Secretin, etc.)

        13.3.  Latin America Endocrine testing Market Value Forecast by Diagnostic Technologies, 2017–2027

            13.3.1. Tandem Mass Spectrometry

            13.3.2. Immunoassay technologies

            13.3.3. Monoclonal and Polyclonal Antibody Technologies

            13.3.4. Sensor Technologies

            13.3.5. Clinical Chemistry Technologies

            13.3.6. Others 

        13.4. Latin America Endocrine testing Market Value Forecast by End-user, 2017–2027

            13.4.1. Hospitals 

            13.4.2. Commercial Laboratories 

            13.4.3. Ambulatory Care Centers

            13.4.4. Home Based tests

            13.4.5. Physician Offices

        13.5. Latin America Endocrine testing Market Value Forecast by Country/Sub-region, 2017–2027

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Latin America Endocrine testing Market Attractiveness Analysis 

            13.6.1. By Test Type

            13.6.2. By Diagnostic Technologies

            13.6.3. By End-user

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Endocrine testing Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Middle East & Africa Endocrine testing Market Value Forecast by Test Type, 2017–2027

            14.2.1. Estradiol (E2) Test

            14.2.2. Follicle Stimulating Hormone (FSH) Test

            14.2.3. Human Chorionic Gonadotropin (hCG) Test 

            14.2.4. Luteinizing Hormone (LH) Test

            14.2.5. Dehydroepiandrosterone sulfate (DHEAS) Test

            14.2.6. Progesterone Test

            14.2.7. Testosterone Test 

            14.2.8. Thyroid Stimulating Hormone (TSH) Test

            14.2.9. Prolactin Test

            14.2.10. Cortisol Test

            14.2.11. Insulin Test

            14.2.12. Others (Gastrin, Thymosin, Secretin, etc.)

        14.3. Middle East & Africa Endocrine testing Market Value Forecast by Diagnostic Technologies, 2017–2027

            14.3.1. Tandem Mass Spectrometry

            14.3.2. Immunoassay technologies

            14.3.3. Monoclonal and Polyclonal Antibody Technologies

            14.3.4. Sensor Technologies

            14.3.5. Clinical Chemistry Technologies

            14.3.6. Others 

        14.4. Middle East & Africa Endocrine testing Market Value Forecast by End-user, 2017–2027

            14.4.1. Hospitals 

            14.4.2. Commercial Laboratories 

            14.4.3. Ambulatory Care Centers

            14.4.4. Home Based tests

            14.4.5. Physician Offices

        14.5. Middle East & Africa Endocrine testing Market Value Forecast by Country/Sub-region, 2017–2027

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Latin America Endocrine testing Market Attractiveness Analysis 

            14.6.1. By Test Type

            14.6.2. By Diagnostic Technologies

            14.6.3. By End-user

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player – Competition Matrix (By Tier and Size of companies)

        15.2. Market Share Analysis/Ranking by Company (2018)

        15.3. Company Profiles

            15.3.1. Abbott Laboratories

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Financial Overview 

                15.3.1.3. Growth Strategies

                15.3.1.4. SWOT Analysis. 

            15.3.2. Thermo Fisher Scientific Inc

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Financial Overview 

                15.3.2.3. Growth Strategies

                15.3.2.4. SWOT Analysis 

            15.3.3.   Beckman Coulter Inc

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Financial Overview 

                15.3.3.3. Growth Strategies

                15.3.3.4. SWOT Analysis 

            15.3.4.   Siemens Healthineers

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Financial Overview 

                15.3.4.3. Growth Strategies

                15.3.4.4. SWOT Analysis

            15.3.5. bioMerieux SA

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Financial Overview 

                15.3.5.3. Growth Strategies

                15.3.5.4. SWOT Analysis 

            15.3.6. Bio-Rad Laboratories Inc

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Financial Overview 

                15.3.6.3. Growth Strategies

                15.3.6.4. SWOT Analysis 

            15.3.7. Agilent Technologies Inc

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Financial Overview 

                15.3.7.3. Growth Strategies

                15.3.7.4. SWOT Analysis 

            15.3.8. Sciex

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Growth Strategies

                15.3.8.3. SWOT Analysis 

            15.3.9  F-Hoffmann La Roche AG

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Financial Overview 

                15.3.9.3 Growth Strategies

                15.3.9.4 SWOT Analysis 

    List of Table

    Table 01: Global Endocrine Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

    Table 02: Global Endocrine Testing Market Value (US$ Mn) Forecast, by Diagnostic Technologies, 2017 2027

    Table 03: Global Endocrine Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    Table 04: Global Endocrine Testing Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 06: North America Endocrine Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 07: North America Endocrine Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

    Table 08: North America Endocrine Testing Market Value (US$ Mn) Forecast, by Diagnostic Technologies, 2017–2027

    Table 09: North America Endocrine Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    Table 10: Europe Endocrine Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 11: Europe Endocrine Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

    Table 12: Europe Endocrine Testing Market Value (US$ Mn) Forecast, by Diagnostic Technologies, 2017–2027

    Table 13: Europe Endocrine Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    Table 14: Asia-Pacific Endocrine Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 15: Asia-Pacific Endocrine Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

    Table 08: Asia-Pacific Endocrine Testing Market Value (US$ Mn) Forecast, by Diagnostic Technologies, 2017–2027

    Table 16: Asia-Pacific Endocrine Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    Table 17: Latin America Endocrine Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 18: Latin America Endocrine Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

    Table 19: Latin America Endocrine Testing Market Value (US$ Mn) Forecast, by Diagnostic Technologies, 2017–2027

    Table 20: Latin America Endocrine Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    Table 21: Middle East & Africa Endocrine Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 22: Middle East & Africa Endocrine Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

    Table 23: Middle East & Africa Endocrine Testing Market Value (US$ Mn) Forecast, by Diagnostic Technologies, 2017–2027

    Table 24: Middle East & Africa Endocrine Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    List of Figure

    Figure 01: Global Endocrine Testing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 02: Global Endocrine Testing Market Value Share, by Test Type, 2018 

    Figure 03: Global Endocrine Testing Market Value Share, by Diagnostic Technologies, 2018

    Figure 04: Global Endocrine Testing Market Value Share, by End-user, 2018

    Figure 05: Global Endocrine Testing Market Value Share, by Region, 2019–2027

    Figure 06: Global Endocrine Testing Market Value Share, by Test Type, 2018-2027

    Figure 07: Global Endocrine Testing Market Attractiveness Analysis, by Test Type, 2019-2027

    Figure 07: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Estradiol (E2) Test

    2019–2027

    Figure 08: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Follicle Stimulating Hormone (FSH) Test, 2019–2027

    Figure 09: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Human Chorionic Gonadotropin (hCG) Test, 2019–2027

    Figure 10: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Luteinizing Hormone (LH) Test, 2019–2027

    Figure 11: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Dehydroepiandrosterone sulfate (DHEAS) Test, 2019–2027

    Figure 12: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Progesterone Test, 2019–2027

    Figure 13: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Testosterone Test, 2019–2027

    Figure 14: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Thyroid Stimulating Hormone (TSH) Test, 2019–2027

    Figure 15: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Prolactin Test, 2019–2027

    Figure 16: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Cortisol Test, 2019–2027

    Figure 17: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Insulin Test, 2019–2027

    Figure 18: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2019–2027

    Figure 19: Global Endocrine Testing Market Value Share, Diagnostic Technologies, 2018-2027

    Figure 20: Global Endocrine Testing Market Attractiveness Analysis, by Diagnostic Technologies, 2019- 2027

    Figure 21: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Tandem Mass Spectrometry, 2019–2027

    Figure 22: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Immunoassay technologies, 2019–2027

    Figure 23: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Monoclonal and Polyclonal Antibody Technologies, 2019–2027

    Figure 24: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Sensor Technologies, 2019–2027

    Figure 25: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Clinical Chemistry Technologies, 2019–2027

    Figure 25: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2019–2027

    Figure 26: Global Endocrine Testing Market Value Share, End-user, 2018-2027

    Figure 27: Global Endocrine Testing Market Attractiveness Analysis, by End-user, 2019- 2027

    Figure 28: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2019–2027

    Figure 29: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Commercial Laboratories, 2019–2027

    Figure 30: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Ambulatory Care Centers, 2019–2027

    Figure 31: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Home Based tests, 2019–2027

    Figure 32: Global Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), by Physician Offices, 2019–2027

    Figure 33: Global Endocrine Testing Market Value Share, by Region, 2018 and 2027

    Figure 34: Global Endocrine Testing Market Attractiveness, by Region, 2019–2027

    Figure 35: North America Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 36: North America Endocrine Testing Market Value Share Analysis, by Country, 2018 and 2027

    Figure 37: North America Endocrine Testing Market Attractiveness Analysis, by Country, 2019 – 2027

    Figure 38: North America Endocrine Testing Market Value Share Analysis, by Test Type, 2018 and 2027

    Figure 39: North America Endocrine Testing Market Attractiveness Analysis, by Test Type, 2019 – 2027

    Figure 40: North America Endocrine Testing Market Value Share Analysis, by Diagnostic Technologies,  2018 and 2027

    Figure 41: North America Endocrine Testing Market Attractiveness Analysis, by Diagnostic Technologies, 2019 – 2027

    Figure 42: North America Endocrine Testing Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 43: North America Endocrine Testing Market Attractiveness Analysis, by End-user, 2019 – 2027

    Figure 44: Europe Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 45: Europe Endocrine Testing Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 46: Europe Endocrine Testing Market Attractiveness Analysis, by Country/Sub-region, 2019 – 2027

    Figure 47: Europe America Endocrine Testing Market Value Share Analysis, by Test Type, 2018 and 2027

    Figure 48: Europe Endocrine Testing Market Attractiveness Analysis, by Test Type, 2019 – 2027

    Figure 49: Europe Endocrine Testing Market Value Share Analysis, by Diagnostic Technologies,  2018 and 2027

    Figure 50: Europe Endocrine Testing Market Attractiveness Analysis, by Diagnostic Technologies, 2019 – 2027

    Figure 51: Europe Endocrine Testing Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 52: Europe Endocrine Testing Market Attractiveness Analysis, by End-user, 2019 – 2027

    Figure 53: Asia-Pacific Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 54: Asia-Pacific Endocrine Testing Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 55: Asia-Pacific Endocrine Testing Market Attractiveness Analysis, by Country/Sub-region, 2019 – 2027

    Figure 56: Asia-Pacific America Endocrine Testing Market Value Share Analysis, by Test Type, 2018 and 2027

    Figure 57: Asia-Pacific Endocrine Testing Market Attractiveness Analysis, by Test Type, 2019 – 2027

    Figure 58: Asia-Pacific Endocrine Testing Market Value Share Analysis, by Diagnostic Technologies,  2018 and 2027

    Figure 59: Asia-Pacific Endocrine Testing Market Attractiveness Analysis, by Diagnostic Technologies, 2019 – 2027

    Figure 60: Asia-Pacific Endocrine Testing Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 61: Asia-Pacific Endocrine Testing Market Attractiveness Analysis, by End-user, 2019 – 2027

    Figure 62: Latin America Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 63: Latin America Endocrine Testing Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 64: Latin America Endocrine Testing Market Attractiveness Analysis, by Country/Sub-region, 2019 – 2027

    Figure 65: Latin America Endocrine Testing Market Value Share Analysis, by Test Type, 2018 and 2027

    Figure 66: Latin America Endocrine Testing Market Attractiveness Analysis, by Test Type, 2019 – 2027

    Figure 67: Latin America Endocrine Testing Market Value Share Analysis, by Diagnostic Technologies,  2018 and 2027

    Figure 68: Latin America Endocrine Testing Market Attractiveness Analysis, by Diagnostic Technologies, 2019 – 2027

    Figure 69: Latin America Endocrine Testing Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 70: Latin America Endocrine Testing Market Attractiveness Analysis, by End-user, 2019 – 2027

    Figure 71: Middle East & Africa Endocrine Testing Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 72: Middle East & Africa Endocrine Testing Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 73: Middle East & Africa Endocrine Testing Market Attractiveness Analysis, by Country/Sub-region, 2019 – 2027

    Figure 74: Middle East & Africa Endocrine Testing Market Value Share Analysis, by Test Type, 2018 and 2027

    Figure 75: Middle East & Africa Endocrine Testing Market Attractiveness Analysis, by Test Type, 2019 – 2027

    Figure 76: Middle East & Africa Endocrine Testing Market Value Share Analysis, by Diagnostic Technologies,  2018 and 2027

    Figure 77: Middle East & Africa Endocrine Testing Market Attractiveness Analysis, by Diagnostic Technologies, 2019 – 2027

    Figure 78: Middle East & Africa Endocrine Testing Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 79: Middle East & Africa Endocrine Testing Market Attractiveness Analysis, by End-user, 2019 – 2027

    Figure 80: Global Endocrine Testing Market Share, by Company, 2018

Copyright © Transparency Market Research, Inc. All Rights reserved